



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/697,828	10/29/2003	Steven D. Rosen	UCAL-138DIV	9294

24353 7590 08/02/2005

BOZICEVIC, FIELD & FRANCIS LLP  
1900 UNIVERSITY AVENUE  
SUITE 200  
EAST PALO ALTO, CA 94303

EXAMINER

MONSHIPOURI, MARYAM

ART UNIT PAPER NUMBER

1653

DATE MAILED: 08/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

10/697,828

Applicant(s)

ROSEN ET AL.

Examiner

Maryam Monshipouri

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-29 is/are pending in the application.
- 4a) Of the above claim(s) 5-29 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-4 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |   |  |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>filed 6/04 &amp; 10/03</u> . | 6) <input checked="" type="checkbox"/> Other: <u>see attachments</u> .                 |

Art Unit: 1653

Applicant's response to restriction requirement filed 6/1/2005 is acknowledged.

Applicant elected Group I invention, claims 1-4 and GST4 $\alpha$  species with traverse. In traversal of restriction requirement applicant argues that it would not be unduly burdensome to perform a search on all the claims together and for that reason the restriction requirement should be withdrawn.

This argument was fully considered but was found **unpersuasive**. This is because as explained in the previous office action, apart from Groups I-II all the inventions of Groups III-VII belong to separate class/subclasses. Hence rejoinder of said inventions clearly does impose an undue burden of searching on the examiner. Applicant is specially reminded that the invention of Group VII needs to be examined in an art unit independent of art unit 1653, wherein current elected invention is being examined.

With respect to inventions of Groups I-II, it should be reminded that even though there may be some overlap between the subject matter of each invention, the searches required for Groups I-II are **not coextensive**. This is because Group II requires a search in class 530/350, which is not relevant to Group I invention. Similarly, the invention of Group I requires a search in class 435/320.1 which is irrelevant to the invention of Group II. Therefore, as applicant can appreciate the rejoinder of Groups I-II also imposes an undue burden of searching on the examiner.

In conclusion, for the reasons set forth above, in addition to reasons provided in the previous office action restriction is maintained and is hereby made **final**.

**DETAILED ACTION**

Claims 1-4 (and GST $\alpha$  species) are under examination on the merits.

Claims 5-29 are withdrawn as drawn to non-elected invention.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 3 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The term "substantially identical" in claim 3 is unclear. Applicant has not defined said term in the specification. It is unclear as how much homology to SEQ ID NO:7 or 8 constitutes "substantial". Appropriate clarification is required.

Claim 4 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It is unclear whether the fragment of glycosyl sulfotransferase of claim 1, namely GST $\alpha$  has to retain transferase activity or not. **For examination purposes it is assumed that fragments claimed retain their glycosyl sulfotransferase activity.**

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-4 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which

Art Unit: 1653

was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 1, 2 and 4 are directed to a genera of glycosyl transferases or fragments thereof that have been merely defined by function.

The court of Appeals for the Federal Circuit has recently held that such a general definition does not meet the requirements of 35 U.S.C. 112, first paragraph. " A written description of an invention involving chemical genus, like a description of a chemical species, requires a precise definition, such as be structure, formula {or} chemical name, of the claimed subject matter sufficient to distinguish it from other materials." *University of California v. Eli Lilly and Co.*, 1997 U.S. App. LEXIS 18221, at \*23, quoting *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). The court held that " in claims involving chemical materials, generic formulae usually indicate with specificity what generic claims encompass. One skilled in the art can distinguish such a formula fro others and can identify many of the species that the claims encompass. accordingly, such a formula is normally an adequate description of the claimed genus. In claims to genetic material, however, a generic statement such as "vertebrate insulin cDNA" or "mammalian insulin cDNA,' without more, is not an adequate written description of the genus because it does not distinguish it from others. One skilled in the art therefore cannot, as one can do with a fully described genus visualize the identity of the members of the genus". Here, in claims 1 and 4, applicant is claiming a genus of proteins merely but they do rather but what they are and such genus does not allow visualization of other members of the genus.

In claim 2, some structural information about the GST4 $\alpha$  is provided but said information is inadequate because human glycosyl sulfotransferase is a large family comprising many members such as GST $\alpha$ , GST4 $\beta$ , GST-3, GST-6 etc. The specification fails to teach how much structural homology exists among all members of human glycosyl sulfotransferase family and specifically how the function of one human species differs from the other and as such the genus of human glycosyl transferases are inadequately described.

With respect to claim 3 as explained above, the term "substantially identical" is unclear. Therefore the structural limitations of the genus of SEQ ID NO:7 and 8 homologs are unclear, rendering the claim subject to written description rejection.

Applicant is referred to the revised interim guidelines concerning compliance with the written description requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at [www.uspto.gov](http://www.uspto.gov).

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-4 are rejected under 35 U.S.C. 102(e) as being anticipated by Bistrup et al. (U.S. Patent No. 6,365,365, issued 4/2002). Bistrup teaches a human glycosyl

Art Unit: 1653

transferase namely GST-3 and fragments thereof prior to this invention. Since glycosyl sulfotransferase of Claim 1 is merely defined by function and the exact functional difference between human GST- $\alpha$  and human GST-3 of Bistrup is not clear it is believed that transferase of Bistrup and fragments thereof meet the limitations of claims 1-2 and 4 of this invention. With respect to claim 3, since the term "substantially identical" is not clear (see the rejection above) it is believed that GST-3 of Bistrup, which has 49.1% identity to SEQ ID NO:8 of this invention (see the attached alignment) can be considered to be "substantially identical" to SEQ ID NO:8 of this invention anticipating claim 3.

Claims 1-4 are rejected under 35 U.S.C. 102(e) as being anticipated by Tang et al. (U.S. Patent No. 6,558,935, issued 5/2003). Tang teaches a human Musculus glycosyl transferase, SEQ ID NO:11 and fragments thereof prior to this invention. Since glycols sulfotransferase of Claim 1 is merely defined by function and the exact functional difference between human GST- $\alpha$  and SEQ ID NO:11 of Tang is not clear it is believed that the transferase of Tang and fragments thereof meet the limitations of claims 1-2 and 4 of this invention. With respect to claim 3, since the term "substantially identical" is not clear (see the rejection above) it is believed that SEQ ID NO:11 of Tang that has 48.0 % identity to SEQ ID NO:7 of this invention (see the attached alignment) can be considered to be "substantially identical" to SEQ ID NO:7 of this invention, anticipating claim 3.

**No claims are allowed.**

Art Unit: 1653

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maryam Monshipouri whose telephone number is (571) 272-0932. The examiner can normally be reached on 7:00 a.m to 4:30 p.m. except for Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Weber Jon P. can be reached on (571) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306 or (571)273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*M. Monshipouri*

Maryam Monshipouri Ph.D.

Primary Examiner

\*\*\*



Attachment

Matches 206; Conservative 56; Mismatches 104; Indels 28; Gaps 7;  
QY 14 LLLAQTCLLFIITSRP-----GSSPAGGEDRVHVLVSSWRSGSSFFGQ 59  
DB 1 MLFPRKMKLLFLVSQAMIALPFHMYSHNISLSMKAPRPMHVLVSSWRSGSSFFGQ 60  
QY 60 LFSQHPVFLMEBAWVWTTLSQSAATLMAVRDLMSIFLDDMVFDAYM-POSRL 118  
DB 61 LFGQHPVFLMEBAWVWTTLSQSAATLMAVRDLMSIFLDDMVFDAYM-POSRL 120  
QY 119 SAFENATSRALCSPPACSAFPRGTISKODVCKTLCTROPESLARACRSYSHVLEVR 178  
DB 121 SSLEFOWENSALCSAPACDIIPODEIIPRACHRLCSQCFEYVEKACRSYSHVLEVR 180  
QY 179 FPNLOVLYPLSLDPALNRIVHLVRDRAVLRSEBAAGPILARDNGIVLGTN-GKWEAD 237  
DB 181 FPNLOVLYPLSLDPALNRIVHLVRDRAVLRSEBAAGPILARDNGIVLGTN-GKWEAD 240  
QY 238 PHRLIREVCRSHVRIAEATLKP-PPPLRGYRLVREDAEPLAEIRALVAFGLTL 296  
DB 241 QPYVWQVTCOSOLEYK-TIOSLPKALQERYLVRVEDLARAIVAQTSRMTEFVGLER 298  
QY 297 TPOLBAMINHTGSGIGKPIBAFHTSSRNARVNSOAMRHALPFTKILRYQVCAALQ 356  
DB 299 LPHLOQVWNTITRGKMGD--HAFHTNARDALNVSQAMWSLPEYKVSRLQKACGDANML 356  
QY 357 LGYRPVYADQGRDLTDLVLPGRDPHFVWASPD-390  
DB 357 LGYRHVRSQEQRNLLDL-----STWTYPE 383

RESULT 5

US-09-190-911-1  
Sequence 1, Application US/09190911  
Patent No. 6365365  
GENERAL INFORMATION:  
APPLICANT: Bistrop, Annette  
APPLICANT: Rensen, Steven D.  
APPLICANT: Tangemann, Kirsten  
APPLICANT: Hemmerich, Stefan  
TITLE OF INVENTION: GLYCOSYL SULFOTRANSFERASE-3  
FILE REFERENCE: 6510-107CTP  
CURRENT APPLICATION NUMBER: US/09/190,911  
CURRENT FILING DATE: 1998-11-12  
EARLIER APPLICATION NUMBER: 09/045,284  
NUMBER OF SEQ ID NOS: 8  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 1  
LENGTH: 386  
TYPE: PRT  
ORGANISM: H. sapiens  
US-09-190-911-1  
Query Match 49.1%; Score 1008; DB 3; Length 386;  
Best Local Similarity 52.3%; Pred. No. 2.7e-105;  
Matches 206; Conservative 56; Mismatches 104; Indels 28; Gaps 7;  
QY 14 LLLAQTCLLFIITSRP-----GSSPAGGEDRVHVLVSSWRSGSSFFGQ 59  
DB 1 MLFPRKMKLLFLVSQAMIALPFHMYSHNISLSMKAPRPMHVLVSSWRSGSSFFGQ 60  
QY 60 LFSQHPVFLMEBAWVWTTLSQSAATLMAVRDLMSIFLDDMVFDAYM-POSRL 118  
DB 61 LFGQHPVFLMEBAWVWTTLSQSAATLMAVRDLMSIFLDDMVFDAYM-POSRL 120  
QY 119 SAFENATSRALCSPPACSAFPRGTISKODVCKTLCTROPESLARACRSYSHVLEVR 178  
DB 121 SSLEFOWENSALCSAPACDIIPODEIIPRACHRLCSQCFEYVEKACRSYSHVLEVR 180  
QY 179 FPNLOVLYPLSLDPALNRIVHLVRDRAVLRSEBAAGPILARDNGIVLGTN-GKWEAD 237  
DB 181 FPNLOVLYPLSLDPALNRIVHLVRDRAVLRSEBAAGPILARDNGIVLGTN-GKWEAD 240

QY 238 PHRLIREVCRSHVRIAEATLKP-PPPLRGYRLVREDAEPLAEIRALVAFGLTL 296  
DB 241 QPYVWQVTCOSOLEYK-TIOSLPKALQERYLVRVEDLARAIVAQTSRMTEFVGLER 298  
QY 297 TPOLBAMINHTGSGIGKPIBAFHTSSRNARVNSOAMRHALPFTKILRYQVCAALQ 356  
DB 299 LPHLOQVWNTITRGKMGD--HAFHTNARDALNVSQAMWSLPEYKVSRLQKACGDANML 356  
QY 357 LGYRPVYADQGRDLTDLVLPGRDPHFVWASPD-390  
DB 357 LGYRHVRSQEQRNLLDL-----STWTYPE 383

RESULT 6

US-09-786-240-11  
Sequence 11, Application US/090786240  
Patent No. 658935  
GENERAL INFORMATION:  
APPLICANT: INCYTE PHARMACEUTICALS, INC  
APPLICANT: TANG, Y. TOM  
APPLICANT: CORLEY, NEAL C.  
APPLICANT: GUEBLES, KATHY O.  
APPLICANT: BAUGHN, MARLENE E.  
APPLICANT: LAL, PRESEIL  
APPLICANT: YUR, HEYU  
APPLICANT: HILLMAN, JENNIFER D.  
APPLICANT: AZIZPAI, FAJED  
TITLE OF INVENTION: HUMAN TRANSFERIN RECEPTOR  
FILE REFERENCE: PF-0592, B  
CURRENT APPLICATION NUMBER: US/09/786,240  
CURRENT FILING DATE: 2002-04-22  
PRIOR APPLICATION NUMBER: 09/150,657, Published: 1999-05-11  
PRIOR FILING DATE: 1998-09-20, 1998-09-19, 1998-09-04, 1998-05-11  
NUMBER OF SEQ ID NOS: 33  
SOFTWARE: PERL Program  
SEQ ID NO 11  
LENGTH: 386  
TYPE: PRT  
ORGANISM: Homo sapiens  
FEATURES:  
NAME/KEY: misc feature  
OTHER INFORMATION: Incyte ID No. 658935 2637407GDL  
US-09-786-240-11  
Query Match 47.3%; Score 970; DB 4; Length 386;  
Best Local Similarity 51.3%; Pred. No. 1.3e-98;  
Matches 202; Conservative 52; Mismatches 150; Indels 28; Gaps 7;  
QY 14 LLLAQTCLLFIITSRP-----GSSPAGGEDRVHVLVSSWRSGSSFFGQ 59  
DB 1 MLFPRKMKLLFLVSQAMIALPFHMYSHNISLSMKAPRPMHVLVSSWRSGSSFFGQ 60  
QY 60 LFSQHPVFLMEBAWVWTTLSQSAATLMAVRDLMSIFLDDMVFDAYM-POSRL 118  
DB 61 LFGQHPVFLMEBAWVWTTLSQSAATLMAVRDLMSIFLDDMVFDAYM-POSRL 120  
QY 119 SAFENATSRALCSPPACSAFPRGTISKODVCKTLCTROPESLARACRSYSHVLEVR 178  
DB 121 SSLEFOWENSALCSAPACDIIPODEIIPRACHRLCSQCFEYVEKACRSYSHVLEVR 180  
QY 179 FPNLOVLYPLSLDPALNRIVHLVRDRAVLRSEBAAGPILARDNGIVLGTN-GKWEAD 237  
DB 181 FPNLOVLYPLSLDPALNRIVHLVRDRAVLRSEBAAGPILARDNGIVLGTN-GKWEAD 240  
QY 238 PHRLIREVCRSHVRIAEATLKP-PPPLRGYRLVREDAEPLAEIRALVAFGLTL 296  
DB 241 QPYVWQVTCOSOLEYK-TIOSLPKALQERYLVRVEDLARAIVAQTSRMTEFVGLER 298  
QY 297 TPOLBAMINHTGSGIGKPIBAFHTSSRNARVNSOAMRHALPFTKILRYQVCAALQ 356  
DB 299 LPHLOQVWNTITRGKMGD--HAFHTNARDALNVSQAMWSLPEYKVSRLQKACGDANML 356

Matches 215; Conservative 43; Mismatches 112; Indels 11; Gaps 7;

QY 1 MLTFRSSTVMTSLMVGITLVF--LVSRQVPS-SPAGLGERVHVLVLSWRSQSSSFV 56  
 DB 1 MLTFR--KMKLLFLVSGMALLALFFHMYSHNISLSKKAQPERHVLVLSWRSQSSSFV 58

QY 57 GOLFSQHPDVFLMEPAHNVMDTSLQSGAPALHMAVRDLISVFLCDMDVDFATL-PMRR 115  
 DB 59 GOLFSQHPDVFLMEPAHNVMDTSLQSGAPALHMAVRDLISVFLCDMDVDFATL-PMRR 118

QY 116 NISLDFQMAVSRALCSPPVCEAFARGNISSEBCKPLCATRPFGLAQEACSSSYSHVVLK 175  
 DB 119 ROSSLFQWENSRALCSAPACDIIPDEIIPRAHCLQERVLVREEDLAPARVAQTSRMTEFVGL 178

QY 176 VRFENLQVLYPLSDPALNRIYHLVDRPRAVLRSEBQTKALARDNGIVLGTNGTWV-E 234  
 DB 179 VRFENLQVLYPLSDPALNRIYHLVDRPRAVLRSEBQTKALARDNGIVLGTNGTWV-E 238

QY 235 ADPRLRVNVEVCRSHVRIAEALHKKPPFLQDRYLRVREEDLAPLTVIRELYAFTGL 294  
 DB 239 EDQPYVWQVLCQSGLEIYK-TIOSLPKALQERVLVREEDLAPARVAQTSRMTEFVGL 297

QY 295 LTPOLQWTHNITGSGPGARREAKTTSRDALSVQAMWHTLPFAKIRVOELCGALQ 354  
 DB 298 FLPHLQWTHNITGSGPGARREAKTTSRDALSVQAMWHTLPFAKIRVOELCGALQ 355

QY 355 LGGYRVSSELEQDLSLDL 375  
 DB 356 LGGYRVSSELEQDLSLDL 376

RESULT 5  
 US-09-190-911-1  
 ; Sequence 1, Application US/09190911  
 ; Patent No. 6365365  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Bistrup, Annette  
 ; APPLICANT: Rosen, Steven D.  
 ; APPLICANT: Tangemann, Kirsten  
 ; APPLICANT: Hemmerich, Stefan  
 ; TITLE OF INVENTION: GLYCOSYL SULFOTRANSFERASE-3  
 ; FILE REFERENCE: 6510-107C1P  
 ; CURRENT APPLICATION NUMBER: US/09/190,911  
 ; CURRENT FILING DATE: 1998-11-12  
 ; EARLIER APPLICATION NUMBER: 09/045,284  
 ; EARLIER FILING DATE: 1998-03-20  
 ; NUMBER OF SEQ ID NOS: 8  
 ; SOFTWARE: FastSeq for Windows Version 3.0  
 ; SEQ ID NO 1  
 ; LENGTH: 386  
 ; TYPE: prt  
 ; ORGANISM: H. sapiens  
 ; US-09-190-911-1

Query Match 49.5%; Score 1017.5; DB 3; Length 386;  
 Best Local Similarity 56.4%; Pred. No. 1.5e-104;  
 Matches 215; Conservative 43; Mismatches 112; Indels 11; Gaps 7;

QY 235 ADPRLRVNVEVCRSHVRIAEALHKKPPFLQDRYLRVREEDLAPLTVIRELYAFTGL 294  
 DB 239 EDQPYVWQVLCQSGLEIYK-TIOSLPKALQERVLVREEDLAPARVAQTSRMTEFVGL 297

QY 295 LTPOLQWTHNITGSGPGARREAKTTSRDALSVQAMWHTLPFAKIRVOELCGALQ 354  
 DB 298 FLPHLQWTHNITGSGPGARREAKTTSRDALSVQAMWHTLPFAKIRVOELCGALQ 355

QY 355 LGGYRVSSELEQDLSLDL 375  
 DB 356 LGGYRVSSELEQDLSLDL 376

## RESULT 6

US-09-786-240-11  
 ; Sequence 11, Application US/09786240  
 ; Patent No. 6558935  
 ; GENERAL INFORMATION:  
 ; APPLICANT: INCYTE PHARMACEUTICALS, INC.  
 ; APPLICANT: TANG, Y. TOM  
 ; APPLICANT: CORLEY, Neil C.  
 ; APPLICANT: GUEGLER, Karl J.  
 ; APPLICANT: BAUGHN, Mariah R.  
 ; APPLICANT: LAL, Preeti  
 ; APPLICANT: YUE, Henry  
 ; APPLICANT: HILLMAN, Jennifer L.  
 ; APPLICANT: AZIMZAI, Yalda  
 ; TITLE OF INVENTION: HUMAN TRANSFERASE PROTEINS  
 ; FILE REFERENCE: PF-0592 PCT  
 ; CURRENT APPLICATION NUMBER: US/09/786,240  
 ; CURRENT FILING DATE: 2002-03-12  
 ; PRIOR APPLICATION NUMBER: 09/150,657; unassigned, 09/186,779; unassigned, 60/133,642  
 ; PRIOR FILING DATE: 1998-09-10; 1998-09-10; 1998-11-04; 1998-11-04; 1999-05-11  
 ; NUMBER OF SEQ ID NOS: 33  
 ; SOFTWARE: PERL Program  
 ; SEQ ID NO 11  
 ; LENGTH: 386  
 ; TYPE: prt  
 ; ORGANISM: Homo sapiens  
 ; NAME/KEY: misc feature  
 ; OTHER INFORMATION: Incyte ID No. 6558935 2617407CD1  
 ; US-09-786-240-11

Query Match 48.0%; Score 986.5; DB 4; Length 386;  
 Best Local Similarity 56.3%; Pred. No. 4.2e-101;  
 Matches 215; Conservative 40; Mismatches 114; Indels 13; Gaps 9;

QY 1 MLTFRSSTVMTSLMVGITLVF--LVSRQVPS-SPAGLGERVHVLVLSWRSQSSSFV 56  
 DB 1 MLTFR--KMKLLFLVSGMALLALFFHMYSHNISLSKKAQPERHVLVLSWRSQSSSFV 58

QY 57 GOLFSQHPDVFLMEPAHNVMDTSLQSGAPALHMAVRDLISVFLCDMDVDFATL-PMRR 115  
 DB 59 GOLFSQHPDVFLMEPAHNVMDTSLQSGAPALHMAVRDLISVFLCDMDVDFATL-PMRR 118

QY 116 NISLDFQMAVSRALCSPPVCEAFARGNISSEBCKPLCATRPFGLAQEACSSSYSHVVLK 174  
 DB 119 ROSSLFQWENSRALCSAPACDIIPDEIIPRAHCLQERVLVREEDLAPARVAQTSRMTEFVGL 177

QY 175 EVRFENLQVLYPLSDPALNRIYHLVDRPRAVLRSEBQTKALARDNGIVLGTNGTWV- 233  
 DB 178 EVRFENLQVLYPLSDPALNRIYHLVDRPRAVLRSEBQTKALARDNGIVLGTNGTWV- 237

QY 234 EADPRLRVNVEVCRSHVRIAEALHKKPPFLQDRYLRVREEDLAPLTVIRELYAFTGL 293  
 DB 238 EADPRLRVNVEVCRSHVRIAEALHKKPPFLQDRYLRVREEDLAPLTVIRELYAFTGL 296

QY 294 GLTPOLQWTHNITGSGPGARREAKTTSRDALSVQAMWHTLPFAKIRVOELCGALQ 353  
 DB 297 GLTPOLQWTHNITGSGPGARREAKTTSRDALSVQAMWHTLPFAKIRVOELCGALQ 354

QY 354 OLGYSRVHSELEQDLSIDL 375  
Db 355 NLGYSRVHSELEQDLSIDL 376

## RESULT 7

US-09-263-023-4  
Sequence 4, Application US/09263023  
Patent No. 6037159  
GENERAL INFORMATION:  
APPLICANT: Uchimura, Kenji  
APPLICANT: Muramatsu, Hideki  
APPLICANT: Kadomatsu, Kenji  
APPLICANT: Kanagaki, Reiji  
APPLICANT: Habuchi, Osami  
APPLICANT: Muramatsu, Takashi  
TITLE OF INVENTION: POLYPEPTIDE OF N-ACETYLGLUCOSAMINE-6-0-SULFOTRANSFERASE AND  
TITLE OF INVENTION: DNA ENCODING THE SAME  
FILE REFERENCE: TOYAMA1.001AUS  
CURRENT APPLICATION NUMBER: US/09/263,023  
EARLIER FILING DATE: 1999-03-05  
EARLIER APPLICATION NUMBER: JP 10-54007  
EARLIER FILING DATE: 1998-03-05  
EARLIER APPLICATION NUMBER: JP 10-177844  
EARLIER FILING DATE: 1998-06-24  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: FASTSEQ for Windows Version 3.0  
SEQ ID NO 4  
LENGTH: 484  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-263-023-4

Query Match 31.5% Score 647.5; DB 3; Length 484;  
Best Local Similarity 36.8%; Pred. No. 4e-63;  
Matches 140; Conservative 76; Mismatches 117; Indels 47; Gaps 9;

QY 33 SPAGIGERVH-VLVLSWRSGSSFFVGOLESQHPDVFLMEPAMHWDTLSGSAFALHMA 91  
Db 110 APEGVGDGRHMVYFTWRSGSSFFGELFNQNPVEFLYEVVHWQKLYGDAVSLGA 169  
QY 92 VRDLIRSVFLCDMDVFDAYLP--WRNISDL--FQWAVRALCSPVCEAFARG--NIS 144  
Db 170 ARDMLSALYICDLSVFLYSPAGSGGNLTLLGIFGATNKVCSSPLCPAYRKVGVGLV 229  
QY 145 SEEVCKELCATRPFGLAQAQSSSHVLEKEVPFNQVLPPLSDPALNRIYHVRDP 204  
Db 230 DDRVCKK-CPQRLARFEBCRKRTLVIGVRFVDAVLAFLRDPALDKVHLVRDP 288  
QY 205 RAVLRSEBOTAKALARDNGIVLGTNGTWEADPR----- 238  
Db 289 RAVASSIRSRHGLRISLQVRSR-----DPAHRMPELEAGHGLAKKEGVGPAD 342  
QY 239 ---LRVNEVCRSHVRAEALHKKPPFLQDRYRLVREYEDLARDPLTVIRELYAFTGIL 295  
Db 343 YHALGMEVICSNAKTLQTL--QPPDLQGHLYVREYEDLVDPVKTLRVYDFVGLV 401  
QY 296 TPOLQTIHNTHTSGPGAREAKFTSRDALSVSQAMRHLPFAKTRVQELCGALQL 355  
Db 402 SPEMEQPALNMTSGSSSSK--PFVVSARNAQTAAANMRTALTFQIKVBEFCYQPMV 459  
QY 356 LGYSRVHSELEQDLSIDL 375  
Db 460 LGYRVHSELEQDLSIDL 479

## RESULT 8

US-09-471-867-4  
Sequence 4, Application US/09471867  
Patent No. 6455289  
GENERAL INFORMATION:  
APPLICANT: Uchimura, Kenji  
APPLICANT: Muramatsu, Hideki

APPLICANT: Kadomatsu, Kenji  
APPLICANT: Kanagaki, Reiji  
APPLICANT: Habuchi, Osami  
APPLICANT: Muramatsu, Takashi  
TITLE OF INVENTION: POLYPEPTIDE OF N-ACETYLGLUCOSAMINE-6-0-SULFOTRANSFERASE AND  
TITLE OF INVENTION: DNA ENCODING THE SAME  
FILE REFERENCE: TOYAMA1.001AUS  
CURRENT APPLICATION NUMBER: US/09/471,867  
EARLIER FILING DATE: 1999-12-23  
EARLIER APPLICATION NUMBER: US 09/263,023  
EARLIER FILING DATE: 1999-03-05  
EARLIER APPLICATION NUMBER: JP 10-54007  
EARLIER FILING DATE: 1998-03-05  
EARLIER APPLICATION NUMBER: JP 10-177844  
EARLIER FILING DATE: 1998-06-24  
NUMBER OF SEQ ID NOS: 10  
SOFTWARE: FASTSEQ for Windows Version 3.0  
SEQ ID NO 4  
LENGTH: 484  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-471-867-4

Query Match 31.5% Score 647.5; DB 4; Length 484;  
Best Local Similarity 36.8%; Pred. No. 4e-63;  
Matches 140; Conservative 76; Mismatches 117; Indels 47; Gaps 9;

QY 33 SPAGIGERVH-VLVLSWRSGSSFFVGOLESQHPDVFLMEPAMHWDTLSGSAFALHMA 91  
Db 110 APEGVGDGRHMVYFTWRSGSSFFGELFNQNPVEFLYEVVHWQKLYGDAVSLGA 169  
QY 92 VRDLIRSVFLCDMDVFDAYLP--WRNISDL--FQWAVRALCSPVCEAFARG--NIS 144  
Db 170 ARDMLSALYICDLSVFLYSPAGSGGNLTLLGIFGATNKVCSSPLCPAYRKVGVGLV 229  
QY 145 SEEVCKELCATRPFGLAQAQSSSHVLEKEVPFNQVLPPLSDPALNRIYHVRDP 204  
Db 230 DDRVCKK-CPQRLARFEBCRKRTLVIGVRFVDAVLAFLRDPALDKVHLVRDP 288  
QY 205 RAVLRSEBOTAKALARDNGIVLGTNGTWEADPR----- 238  
Db 289 RAVASSIRSRHGLRISLQVRSR-----DPAHRMPELEAGHGLAKKEGVGPAD 342  
QY 239 ---LRVNEVCRSHVRAEALHKKPPFLQDRYRLVREYEDLARDPLTVIRELYAFTGIL 295  
Db 343 YHALGMEVICSNAKTLQTL--QPPDLQGHLYVREYEDLVDPVKTLRVYDFVGLV 401  
QY 296 TPOLQTIHNTHTSGPGAREAKFTSRDALSVSQAMRHLPFAKTRVQELCGALQL 355  
Db 402 SPEMEQPALNMTSGSSSSK--PFVVSARNAQTAAANMRTALTFQIKVBEFCYQPMV 459  
QY 356 LGYSRVHSELEQDLSIDL 375  
Db 460 LGYRVHSELEQDLSIDL 479

## RESULT 9

US-09-949-016-6471  
Sequence 6471, Application US/09949016  
Patent No. 6812339  
GENERAL INFORMATION:  
APPLICANT: VENTER, J. Craig et al.  
TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED  
WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF  
FILE REFERENCE: CL001307  
CURRENT APPLICATION NUMBER: US/09/949,016  
EARLIER FILING DATE: 2000-04-14  
EARLIER APPLICATION NUMBER: 60/241,755  
EARLIER FILING DATE: 2000-10-20  
EARLIER APPLICATION NUMBER: 60/237,768  
EARLIER FILING DATE: 2000-10-03  
PRIOR APPLICATION NUMBER: 60/231,498  
PRIOR FILING DATE: 2000-09-08